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Abstract 
 
Objectives: To investigate whether measurement of maternal serum placental growth factor 
(PLGF) at 19-24 weeks’ gestation improves the performance of screening for stillbirths that 
is achieved by a combination of maternal factors, fetal biometry and uterine artery pulsatility 
index (UT-PI) and evaluate the performance of screening of this model for all stillbirths and 
those due to impaired placentation and unexplained or other causes. 
 
Methods: This was a prospective screening study of 70,003 singleton pregnancies including 
268 stillbirths, carried out in two phases. The first phase, which included prospective 
measurements of UT-PI and fetal biometry were available in all cases. The second phase 
included prospective measurements of maternal serum PLGF which were available for 9,870 
live births and 86 antepartum stillbirths. The values of PLGF obtained from this screening 
study were simulated in the remaining cases based on bivariate Gaussian distributions, 
defined by the mean and standard deviations.   Multivariate logistic regression analysis was 
used to determine whether the addition of maternal serum PLGF improved the performance 
of screening that was achieved by a combination of maternal factors, fetal biometry and UT-
PI. 
 
Results: Significant contribution to the prediction of stillbirths was provided by maternal 
factor derived a priori risk, MoM values of PLGF, UT-PI and fetal biometry Z-scores. A model 
combining these variables predicted 58% of all stillbirths and 84% of those due to impaired 
placentation, at false positive rate of 10%; within the impaired placentation group the 
detection rate of stillbirth at <32 weeks’ gestation was higher than that of stillbirth at >37 
weeks (97% vs 61%; p<0.01). 
 
Conclusions: A high proportion of stillbirths due to impaired placentation can be effectively 
identified in the second trimester of pregnancy. 
 
   
Introduction 
 
A screening study of 70,003 singleton pregnancies at 19-24 weeks’ gestation, including 268 
stillbirths, reported that 59% of antepartum stillbirths were associated with preeclampsia 
(PE), birth of small for gestational age (SGA) neonates or placental abruption and these 
were attributed to impaired placentation; 41% were due to other or unexplained causes.1 
Screening for stillbirth by a combination of factors from maternal characteristics and medical 
history predicted 34% of stillbirths due to impaired placentation and 23% of those that were 
due to other or unexplained causes, at false positive rate (FPR) of 10%.1,2 Prediction of 
stillbirth due to impaired placentation was substantially improved by a model combining 
maternal factors, fetal biometry and uterine artery pulsatility index (UT-PI) with DR of 75% at 
FPR of 10%.1 
 
Placental growth factor (PLGF) is an angiogenic protein produced by the placenta and is 
implicated in trophoblastic invasion of maternal spiral arteries.3,4 Maternal serum levels in the 
first, second and third trimesters are decreased in pregnancies with impaired placentation 
that develop PE and those that deliver SGA neonates.5-15 There is also evidence that 
measurement of serum PLGF at 11-13 weeks’ gestation is useful in predicting stillbirth.16 
 
The objective of this study was to investigate whether measurement of maternal serum 
placental growth factor (PLGF) at 19-24 weeks’ gestation improves the performance of 
screening for stillbirths that is achieved by a combination of maternal factors, fetal biometry 
and UT-PI and evaluate the performance of screening of this model for all stillbirths and 
those due to impaired placentation and unexplained or other causes. 
 
 
Methods 
 
Study population 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for routine pregnancy care at 19+0-24+6 weeks’ gestation at 
King’s College Hospital and Medway Maritime Hospital, United Kingdom between March 
2006 and October 2015.1 Gestational age was determined form the measurement of fetal 
head circumference (HC) in the second-trimester or crown-rump length in the first-
trimester.17,18 The study was carried out in two phases: in the first phase, we recorded 
maternal characteristics and medical history, performed ultrasound examination for 
measurement of fetal HC, abdominal circumference (AC) and femur length (FL) and 
measured UT-PI by transvaginal color Doppler.17,19 In the second phase, we also measured 
maternal serum concentration of PLGF using automated analysers which provide 
reproducible results within 40 minutes of blood sampling (DELFIA Xpress system, 
PerkinElmer Life and Analytical Sciences, Waltham, MA, USA or Cobas e411 system, 
Roche Diagnostics, Penzberg, Germany). 
 
Written informed consent was obtained from the women agreeing to participate in a study on 
adverse pregnancy outcome, which was approved by the Ethics Committee of each 
participating hospital. The inclusion criteria for this study were singleton pregnancies that 
delivered a phenotypically normal live birth or stillbirth at >24 weeks’ gestation. We excluded 
pregnancies with aneuploidies, major fetal abnormalities, those ending in a miscarriage, 
termination of pregnancy or stillbirths due to intrapartum causes. Data on pregnancy 
outcome were obtained from the maternity hospital records or the general practitioners of 
women. The hospital maternity records of all women with antepartum stillbirths were 
reviewed to determine if the death was associated with preeclampsia, abruption or the 
birthweight was <10th percentile for gestational age 20 or it was due to other causes or was 
unexplained.  
 
Statistical analysis 
 
The observed measurements of PLGF and UT-PI were log10 transformed to ensure 
homogeneity of variance and make the distribution Gaussian and each measured value was 
expressed as a multiple of the normal median (MoM) after adjustment for those 
characteristics found to provide a substantial contribution to the log10 transformed value.21,22 
The observed measurements of fetal HC, AC and FL were expressed as the respective Z-
score corrected for gestational age.17 The measured values of UT-PI and fetal biometry were 
available in all cases in the study population of 70,003 singleton pregnancies. Maternal 
serum PLGF measurements were available in 9,956 pregnancies, including 86 with stillbirth. 
In all stillbirths and subgroups of stillbirths, mean and standard deviations (SDs) of log10MoM 
PLGF values were estimated; the values for PLGF were then simulated in the remaining 
cases in study population, based on the bivariate Gaussian distributions of the marker in 
stillbirths and live births, defined by the mean and SD (log10MoM). The a priori risk for 
stillbirths was estimated from the algorithm derived from multivariate logistic regression 
analysis of maternal characteristics and history as previously described.2 Univariate and 
multivariate logistic regression analysis was used to determine significance of contribution of 
these biomarkers in prediction of stillbirth and whether the addition of serum PLGF (log10 
MoM) improved the performance of screening that was achieved by a combination of 
maternal factors, Z-scores of fetal biometry and Mom values of UT-PI.1 The variables which 
provided a significant contribution in the multivariate analysis were used to determine the 
patient-specific risk of stillbirth using the equation odds/(1+odds), where odds=eY and Y was 
estimated from the coefficients of variables in the logistic regression analysis. The 
distribution of patient-specific risks was used to determine the performance of screening by 
receiver operating characteristic (ROC) curves analysis and the DR and FPR were 
estimated.  
 
The statistical software package SPSS 22.0 (IBM SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp, 2013) and Medcalc (Medcalc Software, Mariakerke, Belgium) 
were used for the data analyses. 
 
 
Results 
 
Study population 
 
The maternal and pregnancy characteristics of the total study population of 70,003 singleton 
pregnancies is as previously described (sTable 1)1. Maternal serum PLGF values were 
available in 9,956 singleton pregnancies, including 9,870 live births and 86 antepartum 
stillbirths; maternal and pregnancy characteristics of this group are shown in sTables 2. 
 
Biomarkers in outcome groups 
 
In the stillbirth group, compared to live births, the PLGF MoM was lower (0.65 vs 1.00, 
p<0.0001), UT-PI MoM was higher (1.37 vs 1.00, p<0.0001) and the Z-scores of HC, AC and 
FL were lower (-0.20 vs -0.01, p<0.0001; -0.29 vs. 0.0, p<0.0001; -0.12 vs -0.01, p=0.012, 
respectively). In the stillbirths due to impaired placentation, compared to live births, the 
PLGF MoM was lower (0.42 vs 1.00, p<0.0001), UT-PI MoM was higher (1.68 vs 1.00, 
p<0.0001) and the Z-scores of HC, AC and FL were lower (-0.38 vs -0.01, p<0.0001; -0.66 
vs. 0.0, p<0.0001; -0.46 vs -0.01, p<0.0001, respectively); in the stillbirths due to 
unexplained causes there were no significant differences from live births in any of the 
biomarkers (sTable 3 and Figure 1). 
 
Prediction of stillbirth and performance of combined screening 
 
The results of univariate and multivariate regression analysis are shown in sTable 4. In the 
multivariate regression analysis, there was a significant contribution to the prediction of 
stillbirths due to impaired placentation from maternal factor derived a priori risk, PLGF MoM, 
UT-PI MoM and Z-scores of HC and AC but not FL (R2=0.482; p<0.0001). The performance 
of screening for stillbirth is shown in Table 1 and Figure 2.  
 
The DR for all stillbirths, at FPR of 10%, increased from 55% in screening by a combination 
of maternal factors, fetal biometry and UT-PI to 58% with the addition of serum PLGF; the 
respective values for the impaired placentation group were 75% and 84%. Within the 
impaired placentation group the DR with the combined model was higher for stillbirths at <32 
weeks’ gestation than those at >37 weeks (97% vs 61%; p<0.01). 
 
 
Discussion 
 
Main findings of the study 
 
The findings of the study demonstrate that a high proportion of stillbirths due to impaired 
placentation can be effectively identified by second trimester screening by a combination of 
maternal factors, serum PLGF, fetal biometry and UT-PI. Such combined screening at 19-24 
weeks can potentially predict 84% all stillbirths due to impaired placentation, at a 10% FPR; 
the performance of screening is better for stillbirths <32 weeks’ gestation (97%), compared 
to those at term (61%).  
 
Strengths and limitations 
 
The strengths of this screening study are first, examination of a large population of pregnant 
women attending for routine assessment at 19-24 weeks’ gestation, second, systematic 
recording of data on maternal characteristics and medical history to identify known risk 
factors associated with stillbirth, third, use of a specific methodology and appropriately 
trained doctors to measure UT-PI, fourth, use of automated machines to provide accurate 
measurement of maternal serum PLGF concentration within 40 minutes of sampling, fifth, 
expression of the values of biomarkers as MoMs after adjustment for factors that affect the 
measurements, and sixth, use of multivariate regression analysis to take into account 
possible interrelations between the different variables to define the relative predictive value 
of each factor.  
 
Potential limitations of the study include estimation of performance based on simulation of 
PLGF values; however, there was no significant difference between the bivariate Gaussian 
distributions of the measured and simulated values. Another potential limitation is that the 
performance of screening by a model derived and tested using the same dataset is 
overestimated; consequently, the model needs validation from prospective studies.  
 
Comparison with other studies 
 
Previous studies in the second trimester have reported the benefit of incorporating 
measurement of serum PLGF in models of screening for PE and SGA.7,10,13 Previous 
second-trimester studies have highlighted the value of uterine artery Doppler in screening for 
stillbirth.1,23-25 Our study demonstrated the value of combining maternal factors, fetal 
biometry, UT-PI and PLGF in screening for stillbirth.  
 
Clinical implications of the study 
 
Prevention of impaired placentation related stillbirth could potentially be achieved by a two 
stage screening and intervention strategy. The first stage, at 11-13 weeks, would aim at 
improving placentation through such pharmacological interventions as low-dose aspirin and 
pravastatin in the high-risk group;26,27 first-trimester screening by a combination of maternal 
factors, UT-PI, fetal ductus venosus pulsatility index for veins and maternal serum PLGF 
could detect about 60% of stillbirths due to impaired placentation, at FPR of 10%.16 The 
second stage, at 19-24 weeks would identify a high-risk group that could benefit from close 
monitoring for early diagnosis of PE and SGA and appropriate management to prevent 
stillbirth in such pregnancies; as demonstrated in this study about 85% of stillbirths could be 
predicted from combined screening at 20 weeks’ gestation. 
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Table 1. Performance of screening for stillbirths by maternal factors, uterine artery pulsatility 
index and fetal biometry, without and with placental growth factor at 19-24 weeks’ gestation 
at fixed false positive rates of 5% and 10%. 
 
Outcome  N AUROC (95% CI) 
Detection rates (95% CI) 
5% FPR 10% FPR 
All stillbirths 268  
Maternal factors, UT-PI, biometry  0.748 (0.711-0.785) 45.1 (39.1-51.0) 54.7 (48.7-60.6) 
     + PLGF  0.781 (0.746-0.817) 50.7 (44.7-56.7) 57.6 (51.7-63.5) 
Abnormal placentation  
All stillbirths 159    
Maternal factors, UT-PI, biometry  0.904 (0.875-0.933) 69.8 (62.7-76.9) 74.8 (68.1-81.6) 
     + PLGF  0.950 (0.932-0.967) 76.1 (69.5-82.7) 83.6 (77.8-89.4) 
< 32 weeks 90    
Maternal factors, UT-PI, biometry  0.952 (0.921-0.982) 85.6 (78.4-92.9) 87.8 (81.0-94.6) 
     + PLGF  0.990 (0.983-0.998) 94.4 (89.7-99.2) 96.7 (93.1-100.0) 
< 37 weeks 126    
Maternal factors, UT-PI, biometry  0.929 (0.899-0.959) 79.4 (72.3-86.5) 82.5 (75.9-89.1) 
     + PLGF  0.973 (0.960-0.985) 84.1 (77.7-90.5) 89.7 (84.5-95.0) 
> 37 weeks 33    
Maternal factors, UT-PI, biometry  0.810 (0.743-0.877) 33.3 (17.2-49.4) 45.5 (28.4-62.4) 
     + PLGF  0.863 (0.802-0.923) 45.5 (28.5-62.5) 60.6 (43.9-77.3) 
 
AUROC = area under receiver operating characteristic curves; CI = confidence interval; UT-
PI = uterine artery pulsatility index; PLGF = placental growth factor; FPR = false positive rate 
 
 
 
 
 
 
 
Supplementary table 1. Maternal and pregnancy characteristics in pregnancies that had a stillbirth, stratified according to sub-groups, 
compared with pregnancies with live births. 
 
Maternal characteristics 
Live births 
(n=69,735) 
Stillbirths 
All cases 
(n=268) 
Unexplained 
(n=109) 
Impaired placentation 
(n=159) 
Age, median (IQR) 30.5 (25.8-34.5) 30.5 (25.8-35.4) 30.9 (26.1-35.5) 30.4 (25.5-35.4) 
Weight, median (IQR) 67.0 (59.2-78.0) 73.4 (63.7-85.2)* 71.6 (64.2-84.0)* 74.0 (63.5-85.8)* 
Height, median (IQR) 1.64 (1.60-1.69) 1.65 (1.60-1.68) 1.65 (1.62-1.68) 1.63 (1.60-1.68) 
Racial origin     
     Caucasian, n (%) 48,794 (70.0) 144 (53.7) 65 (59.6) 79 (49.7) 
     Afro-Caribbean, n (%) 15,053 (21.6) 103 (38.4) 39 (35.8)* 64 (40.3)* 
     South Asian, n (%) 2,775 (4.0) 9 (3.4) 1 (0.9) 8 (5.0) 
     East Asian, n (%) 1,363 (2.0) 5 (1.9) 1 (0.9) 4 (2.5) 
     Mixed, n (%) 1,750 (2.5) 7 (2.6) 3 (2.8) 4 (2.5) 
Method of conception     
     Spontaneous, n (%) 67,777 (97.2) 255 (95.1) 105 (96.3) 150 (94.3) 
     Assisted conception, n (%) 1,958 (2.8) 13 (4.9) 4 (3.7) 9 (5.7) 
Cigarette smoking, n (%) 7,478 (10.7) 35 (13.1) 14 (12.8) 21 (13.2) 
Chronic hypertension, n (%) 1,031 (1.5) 17 (6.3)* 2 (1.8) 15 (9.4)* 
SLE / APS, n (%) 132 (0.2) 4 (1.5)* 0 4 (2.5)* 
Diabetes mellitus, n (%) 638 (0.9) 7 (2.6) † 3 (2.8) 4 (2.5) 
Parity     
     Nulliparous, n (%) 34,279 (49.2) 132 (49.3) 56 (51.4) 76 (47.8) 
     Previous miscarriage, n (%) 883 (1.3) 4 (1.5) 2 (1.8) 2 (1.3) 
     Previous stillbirth, n (%) 604 (0.9) 15 (5.6)* 3 (2.8) 12 (7.5)* 
     Previous SGA, n (%) 2,315 (3.3) 12 (4.5) 2 (1.8) 10 (6.3) 
Inter-pregnancy interval, median (IQR)a 3.0 (2.0-5.1) 4.2 (2.2-7.1)* 3.9 (2.2-7.0) 4.3 (2.2-8.0)† 
 
Post hoc Bonferroni correction for multiple comparisons; † = p< 0.01; * = p< 0.001 
IQR=interquartile range; SLE=systemic lupus erythematosus; APS=anti-phospholipid syndrome; SGA= small for gestational age 
a Inter-pregnancy interval median (IQR) reported for parous women  
Supplementary table 2. Maternal and pregnancy characteristics in pregnancies that had a stillbirth, stratified according to sub-groups, 
compared with pregnancies with live births 
 
Maternal characteristics 
Live births 
(n=9,870) 
Stillbirths 
All cases 
(n=86) 
Unexplained 
(n=41) 
Impaired placentation 
(n=45) 
Age, median (IQR) 31.1 (26.6-34.8) 32.0 (26.6-35.7) 31.0 (25.1-36.6) 33.4 (26.6-35.5) 
Weight, median (IQR) 67.0 (59.0-78.0) 75.4 (63.5-87.3)* 75.0 (62.9-85.6) 76.0 (63.8-88.8)* 
Height, median (IQR) 1.65 (1.60-1.69) 1.64 (1.60-1.67) 1.64 (1.61-1.67) 1.65 (1.60-1.69) 
Racial origin     
     Caucasian, n (%) 7,234 (73.3) 52 (60.5) 25 (61.0) 27 (60.0) 
     Afro-Caribbean, n (%) 1,812 (18.4) 28 (32.6)* 14 (34.1)* 14 (31.1) 
     South Asian, n (%) 412 (4.2) 1 (1.2) 0 1 (2.2) 
     East Asian, n (%) 194 (2.0) 2 (2.3) 0 2 (4.4) 
     Mixed, n (%) 218 (2.2) 3 (3.5) 2 (4.9) 1 (2.2) 
Method of conception     
     Spontaneous, n (%) 9,523 (96.5) 84 (97.7) 40 (97.6) 44 (97.8) 
     Assisted conception, n (%) 347 (3.5) 2 (2.3) 1 (2.4) 1 (2.2) 
Cigarette smoking, n (%) 999 (10.1) 14 (16.3) 8 (19.5) 6 (13.3) 
Chronic hypertension, n (%) 139 (1.4) 3 (3.5) 1 (2.4) 2 (4.4) 
SLE / APS, n (%) 18 (0.2) 1 (1.2) 0 1 (2.2) 
Diabetes mellitus, n (%) 100 (1.0) 4 (4.7)* 2 (4.9) 2 (4.4) 
Parity     
     Nulliparous, n (%) 4,751 (48.1) 42 (48.8) 20 (48.8) 22 (48.9) 
     Previous miscarriage, n (%) 118 (1.2) 1 (1.2) 1 (2.4) 0 
     Previous stillbirth, n (%) 71 (0.7) 5 (5.8)* 1 (2.4) 4 (8.9)* 
     Previous SGA, n (%) 288 (2.9) 5 (5.8) 2 (4.9) 3 (6.7) 
Inter-pregnancy interval, median (IQR)a 3.0 (1.9-5.0) 4.0 (2.7-6.1) 3.9 (2.6-5.9) 4.0 (2.7-6.3) 
 
Post hoc Bonferroni correction for multiple comparisons; * = p< 0.01 
IQR=interquartile range; SLE=systemic lupus erythematosus; APS=anti-phospholipid syndrome; SGA= small for gestational age 
a Inter-pregnancy interval median (IQR) reported for parous women  
Supplementary table 3. Median and interquartile range of placental growth factor, uterine artery pulsatility index and fetal biometry at 19-24 
week’s gestation in pregnancies with livebirths compared to those that had a stillbirth 
 
Biomarker 
Live births 
(n=9,870) 
Stillbirths 
All cases 
(n=86) 
Unexplained 
(n=41) 
Impaired placentation 
(n=45) 
Placental growth factor (MoM) 1.00 (0.74-1.36) 0.65 (0.34-1.15)** 1.13 (0.64-1.52) 0.42 (0.16-0.68)** 
Uterine artery pulsatility index (MoM) 1.00 (0.84-1.21) 1.37 (1.01-1.71)** 1.17 (0.80-1.38) 1.68 (1.23-2.06)** 
Head circumference z-score -0.01 (-0.33-0.29) -0.20 (-0.57-0.17)** -0.08 (-0.29-0.42) -0.38 (-0.81 - -0.17)** 
Abdominal circumference z-score 0.00 (-0.40-0.38) -0.29 (-0.71-0.11)** 0.06 (-0.27-0.47) -0.66 (-1.16 - -0.28)** 
Femur length z-score -0.01 (-0.35-0.30) -0.12 (-0.56-0.23)* 0.11 (-0.23-0.38) -0.46 (-0.86 - -0.21)** 
 
MoM= multiple of the median; Significance value (p): Post hoc Bonferroni correction for multiple comparisons; * = p< 0.01; ** = p< 0.001 
 
 
 
Supplementary Table 4. Univariate and multivariate logistic regression analysis for the 
prediction of stillbirths due to impaired placentation by maternal factors and combination of 
placental growth factor, uterine artery pulsatility index and fetal biometry at 19-24 week’s 
gestation 
 
 
MoM= multiple of the median; OR = odds ratio; CI = confidence interval 
  
Variables 
Univariate analysis Multivariate analysis 
OR (95% CI) P value OR (95% CI) P value 
Maternal factor derived logit (a priori risk) 14.52 (9.29-22.69) <0.0001 4.84 (2.53-9.28) <0.0001 
Log10 uterine artery pulsatility index MoM 22.75e4 (73.20e3-70.72e4) <0.0001 4.20e3 (1.06e3-16.69e3) <0.0001 
Head circumference z-score 0.07 (0.05-0.09) <0.0001 0.50 (0.32-0.77) 0.002 
Abdominal circumference z-score 0.09 (0.07-0.12) <0.0001 0.31 (0.22-0.43) <0.0001 
Log10 placental growth factor MoM 0.001 (0.001-0.002) <0.0001 0.007 (0.004-0.012) <0.0001 
Figure 1. Box and whiskers plot of placental growth factor in live births (a), unexplained 
stillbirths (b) and stillbirths due to impaired placentation (c). The bottom and top edges of 
each box represent the first and third quartiles, respectively; the band within the box 
represents the median value. 
 
Figure 2. Receiver–operating characteristics curves for prediction of stillbirth due to impaired 
placentation from combined screening with maternal factors, fetal biometry and uterine 
artery pulsatility index (blue curve) and with addition of maternal serum placental growth 
factor (red curve).  
 
